Pharmacopsychiatry
January 19, 2022
Hitoshi Sakurai, Kengo Yonezawa, Hideaki Tani et al.
35 citations
Nine antidepressant compounds with mechanisms beyond the monoaminergic hypothesis have shown positive results in phase II or III trials. AXS-05 (dextromethorphan and bupropion) and ansofaxine hydrochloride outperformed placebo in phase III trials for major depressive disorder or treatment-resistant depression. MIJ821, nitrous oxide, psilocybin, ayahuasca, botulinum toxin A facial injection, prasterone, and casopitant each showed at least one positive phase II result. Ayahuasca produced a greater response rate than placebo at one week, suggesting rapid antidepressant effects. These novel compounds may expand treatment options if preliminary findings are confirmed.
Pharmacopsychiatry
July 30, 2023
Kengo Yonezawa, H. Uchida, T. Yatomi et al.
8 citations
Later age of depression onset is linked to a better treatment response three days after intravenous ketamine in adults with treatment-resistant depression. In a placebo-controlled, double-blind, randomized trial of 31 patients (13 women; average age 48.4 years), logistic regression showed that older age at onset positively correlated with response after three days. No associations were found between response and age, sex, baseline depression severity, or dissociative symptoms. Multiple regression found no factors significantly correlated with change in depression scores. The authors suggest that earlier onset may impair glutamatergic signaling and neuroplasticity, reducing ketamine's effectiveness.
PCN reports : psychiatry and clinical neurosciences
September 1, 2023
Chisato Tanaka, Kenta Wakaizumi, Akira Ninomiya et al.
3 citations
Among graduates of mindfulness-based interventions (MBIs) during the COVID-19 pandemic, those who continued regular mindfulness practice reported lower depression and higher resilience, overall health, and mental health compared to those who did not practice. The degree of perceived stress from the pandemic did not differ statistically between the groups. The effect of mindfulness practice on reducing depression was fully mediated by resilience. The findings suggest that maintaining mindfulness practice after an MBI builds resilience, which helps buffer against new stressors and may prevent depression.
Frontiers in Psychiatry
January 1, 2024
Mitsuhiro Sado, Akihiro Koreki, Akira Ninomiya et al.
For patients with panic disorder or social anxiety disorder, adding mindfulness-based cognitive therapy (MBCT) to usual care costs about JPY 13,885 more per patient over 8 weeks but improves anxiety symptoms and quality of life. The incremental cost per quality-adjusted life year (QALY) was JPY 1,566,357, well below Japan's willingness-to-pay threshold of JPY 5,000,000, giving a 77.5% probability of being cost-effective. MBCT reduced state anxiety by 10.13 points and trait anxiety by 12.00 points on the STAI. Sensitivity analyses confirmed the findings were robust.
JMIR Research Protocols
August 28, 2023
Mitsuhiro Sado, Akira Ninomiya, Maki Nagaoka et al.
A feasibility randomized controlled trial compares augmented mindfulness-based cognitive therapy (MBCT) with follow-up sessions to augmented MBCT without follow-up sessions for adults aged 20–65 with panic disorder, agoraphobia, or social anxiety disorder that has not remitted after at least 4 weeks of usual treatment. The 8-week MBCT program includes a 10-month follow-up period. Primary outcomes are inclusion rate, dropout rate, attendance rate, and clinical measures at 8 weeks and 5, 8, and 12 months. Recruitment began in January 2020 and 43 participants were enrolled by January 2021; data collection is expected to finish by May 2022. The study is limited by mixed intervention delivery modes and lack of a pharmacotherapy-alone arm.
Frontiers in Psychology
September 4, 2021
Teppei Kosugi, Akira Ninomiya, Maki Nagaoka et al.
Eight weeks of mindfulness-based cognitive therapy, followed by two monthly classes, improves both cognitive and affective aspects of subjective well-being and eudaimonic well-being in healthy community residents with initially low life satisfaction. Cognitive well-being and mindfulness skills improved significantly by 8 weeks, and these gains continued through the 16-week follow-up. Positive affect and eudaimonic well-being showed significant improvement only at 16 weeks. The order of improvement was cognitive, then positive affective, then eudaimonic well-being.